Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

References

• DavìGPatronoCPlatelet activation and atherothrombosisN Eng J Med20073572424822494
   PubMed Web of Science ®Google Scholar
• AngiolilloDJUenoMGotoSBasic principles of platelet biology and clinical implicationsCirc J201074459760720197627
   PubMed Web of Science ®Google Scholar
• UenoMKodaliMTello-MontoliuAAngiolilloDJRole of platelets and antiplatelet therapy in cardiovascular diseaseJ Atheroscler Thromb201118643144221427504
   PubMed Web of Science ®Google Scholar
• AngiolilloDJThe evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present dayDrugs201272162087211623083110
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEVariability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectivesJ Am Coll Cardiol200749141505151617418288
   PubMed Web of Science ®Google Scholar
• TantryUSBonelloLAradiDConsensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingJ Am Coll Cardiol201362242261227324076493
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• LeonCAlexMKlockeAPlatelet ADP receptors contribute to the initiation of intravascular coagulationBlood2004103259460012969982
   PubMed Web of Science ®Google Scholar
• van der MeijdenPEFeijgeMAGiesenPLHuijbertsMvan RaakLPHeemskerkJWPlatelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic riskThromb Haemost20059361128113615968399
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCapranzanoPDesaiBImpact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patientsThromb Res2009124331832219012950
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCapodannoDGotoSPlatelet thrombin receptor antagonism and atherothrombosisEur Heart J2010311172819948715
   PubMed Web of Science ®Google Scholar
• CapodannoDBhattDLGotoSSafety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trialsJ Thromb Haemost201210102006201522845871
   PubMed Web of Science ®Google Scholar
• TricociPHuangZHeldCThrombin-receptor antagonist vorapaxar in acute coronary syndromesN Engl J Med20123661202322077816
   PubMed Web of Science ®Google Scholar
• MorrowDABraunwaldEBonacaMPVorapaxar in the secondary prevention of atherothrombotic eventsN Engl J Med2012366151404141322443427
   PubMed Web of Science ®Google Scholar
• MartorellLMartínez-GonzálezJRodríguezCGentileMCalvayracOBadimonLThrombin and protease-activated receptors (PARs) in atherothrombosisThromb Haemost200899230531518278179
   PubMed Web of Science ®Google Scholar
• UenoMFerreiroJLAngiolilloDJMechanism of action and clinical development of platelet thrombin receptor antagonistsExpert Rev Cardiovasc Ther2010881191120020670195
   PubMedGoogle Scholar
• CoughlinSRProtease-activated receptors in hemostasis, thrombosis and vascular biologyJ Thromb Haemost2005381800181416102047
   PubMed Web of Science ®Google Scholar
• KahnMLZhengYWHuangWA dual thrombin receptor system for platelet activationNature199839466946906949716134
   PubMed Web of Science ®Google Scholar
• VuT-KHHungDTWheatonVICoughlinSRMolecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell1991646105710681672265
   PubMed Web of Science ®Google Scholar
• KahnMLNakanish-MatsuiMShapiroMJIshiharaHCoughlinSRProtease-activated receptors 1 and 4 mediate activation of human platelets by thrombinJ Clin Invest1999103687988710079109
   PubMed Web of Science ®Google Scholar
• XuWFAndersonHWhitemoreTECloning and characterization of human protease-activated receptor 4Proc Natl Acad Sci U S A19989512664266469618465
   PubMed Web of Science ®Google Scholar
• HenriksenRAHanksVKPAR-4 agonist AYPGKF stimulates thromboxane production by human plateletsArterioscler Thromb Vasc Biol200222586186612006403
   PubMed Web of Science ®Google Scholar
• CovicLSinghCSmithHKuliopulosARole of PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndromeThromb Haemost200287472272712008957
   PubMed Web of Science ®Google Scholar
• LovaPCampusFLombardiRContribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombinJ Biol Chem200427924252992530615078882
   PubMed Web of Science ®Google Scholar
• SmithCCWilsonAPPrichardBNBetteridgeDJStimulus-induced release of endogenous catecholamines from human washed plateletsClin Sci (Lond)19867054955003698518
   PubMed Web of Science ®Google Scholar
• HennVSlupskyJRGrafeMCD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cellsNature199839166675915949468137
   PubMed Web of Science ®Google Scholar
• StenbergPEMcEverRPShumanMAJacquesYVBaintonDFA platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activationJ Cell Biol198510138808862411738
   PubMed Web of Science ®Google Scholar
• OffermannsSToombsCFHuYHSimonMIDefective platelet activation in G alpha(q)-deficient miceNature199738966471831869296496
   PubMed Web of Science ®Google Scholar
• KatoYKitaYHirasawa-TaniyamaYInhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pigEur J Pharmacol20034732–316316912892834
   PubMed Web of Science ®Google Scholar
• ChackalamannilSDaviesRJAsberomTDollerDLeoneDA highly efficient total synthesis of (+)-himbacineJ Am Chem Soc19961184098129813
   Web of Science ®Google Scholar
• DollerDChakalamannilSCzarnieckiMMcQuadeRRupertoVDesign, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonistsBioorg Med Chem Lett19999690190610206558
   PubMed Web of Science ®Google Scholar
• XiaYChackalamannilSGreenleeWJDiscovery of a vorapaxar analog with increased aqueous solubilityBioorg Med Chem Lett201020226676667920888225
   PubMed Web of Science ®Google Scholar
• KosoglouTReydermanLTiessenRTRAP-induced platelet aggregation following single and multiple rising doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteersPharmacol Ther200985Suppl 1S21
   Google Scholar
• KosoglouTReydermanLTiessenRGPharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjectsEur J Clin Pharmacol201268324925821935705
   PubMed Web of Science ®Google Scholar
• KosoglouTReydermanLKasserraCNo differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjectsEur J Clin Pharmacol201268329130021969227
   PubMed Web of Science ®Google Scholar
• BeckerRCMoliternoDJJenningsLKSafety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II studyLancet2009373966791992819286091
   PubMed Web of Science ®Google Scholar
• Business WireMerck says additional information provided to investigators in clinical study of vorapaxar2011 Available from: http://www.businesswire.com/news/home/20110119006900/en/Merck-Additional-Information-Investigators-Clinical-Study-VorapaxarAccessed January 3, 2014
   Google Scholar
• LeonardiSTricociPWhiteHDEffect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trialEur Heart J201334231723173123530022
   PubMed Web of Science ®Google Scholar
• ThygesenKAlpertJSJaffeASSimoonsMLChaitmanBRWhiteHDThird universal definition of myocardial infarctionJ Am Coll Cardiol201260161581159822958960
   PubMed Web of Science ®Google Scholar
• WhellanDJTricociPChenEVorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trialJ Am Coll Cardiol Epub1162013
   PubMedGoogle Scholar
• BoyleEMJrLilleSTAllaireEClowesAWVerrierEDEndothelial cell injury in cardiovascular surgery: atherosclerosisAnn Thorac Surg19976338858949066432
   PubMed Web of Science ®Google Scholar
• ReillyCFMcFallRCPlatelet-derived growth factor and transforming growth factor beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cellsJ Biol Chem199126615941994272033043
   PubMed Web of Science ®Google Scholar
• VerrierEDBoyleEMJrEndothelial cell injury in cardiovascular surgeryAnn Thorac Surg19966239159228784042
   PubMedGoogle Scholar
• Ben-YehudaOVorapaxar in patients undergoing CABG: insights from a subgroup analysisJ Am Coll Cardiol Epub1162013
   Google Scholar
• ValgimigliMTricociPHuangZVorapaxar, a platelet thrombin-receptor antagonist, in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from the TRACER trialCirculation2012126A18805
   Google Scholar
• TricociPHuangZvan de WerfFNet clinical benefit of vorapaxar in NSTE ACS: role of ischemic and bleeding risk stratificationCirculation2012126A19049
   Web of Science ®Google Scholar
• TricociPHuangZvan de WerfFVorapaxar with and without thienopyridine use in acute coronary syndromes: results from the TRACER trialEur Heart J20123349549621951627
   PubMedGoogle Scholar
• PetersRJMehtaSRFoxKAEffects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) studyCirculation2013108141682169714504182
   PubMedGoogle Scholar
• CURRENT-OASIS 7 InvestigatorsMehtaSRBassandJPDose comparisons of clopidogrel and aspirin in acute coronary syndromesN Engl J Med20103631093094220818903
   PubMed Web of Science ®Google Scholar
• KohliPUdellJAMurphySADischarge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38)J Am Coll Cardiol201463322523224140678
   PubMedGoogle Scholar
• MahaffeyKWWojdylaDMCarrollKTicagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialCirculation2011124554455421709065
   PubMed Web of Science ®Google Scholar
• MahaffeyKWHuangZWallentinLAssociation of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Am J Cardiol Epub12252013
   PubMedGoogle Scholar
• StoreyRFKothaJSmythSEffects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyThromb Haemost20141115
   Web of Science ®Google Scholar
• DorsamRTTulucMKunapuliSPRole of protease-activated and ADP receptor subtypes in thrombin generation on human plateletsJ Thromb Haemost20042580481215099288
   PubMed Web of Science ®Google Scholar
• MorrowDAAlbertsMJMohrJPEfficacy and safety of vorapaxar in patients with prior ischemic strokeStroke201344369169823396280
   PubMed Web of Science ®Google Scholar
• SciricaBMBonacaMPBraunwaldEVorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialLancet201238098501317132422932716
   PubMed Web of Science ®Google Scholar
• SciricaBMBonacaMPMoraisJVorapaxar in patients with diabetes and prior MI: findings from the TRA 2P-TIMI 50 trialCirculation2013128A10398
   Google Scholar
• BonacaMPSciricaBMCreagerMAVorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50Circulation2013127141522152923501976
   PubMed Web of Science ®Google Scholar
• BonacaMPSciricaBMBraunwaldEEfficacy of vorapaxar is not modified by thienopyridine therapy: results from TRA 2P-TIMI 50 trialCirculation2012126A18595
   Web of Science ®Google Scholar
• SciricaBMBonacaMPBraunwaldEVorapaxar for secondary prevention after myocardial infarction according to aspirin dose – insights from the TRA 2P-TIMI 50 trialCirculation2012126A14508
   Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBDabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• FriedlandSNEisenbergMJShimonyAMeta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary interventionAm J Cardiol2012109101397140422381162
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationVorapaxar Advisory Committee briefing document2014 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm381330.pdfAccessed January 31, 2014
   Google Scholar
• FerreiroJLAngiolilloDJNew directions in antiplatelet therapyCirc Cardiovasc Interv20125343344522715450
   PubMed Web of Science ®Google Scholar